Sales: $237 million
Key personnel: Ron Lombardi, chairman, president and chief executive officer; Christine Sacco, chief financial officer; William P’Pool, senior vice president, general counsel and corporate secretary; Jeanne Collins, vice president of marketing; Mary Beth Fritz, senior vice president, quality and regulatory affairs; Jeff Zerillo, senior vice president, operations
Major products: A range of health and personal care products including oral care, OTC skin care, pain products, digestive aids, women’s and children’s health and more. Oral care: DenTek, Efferdent, Effergrip, FreshGuard, GlyOxide, Orabrush and The Doctor’s Night Guard. Skin care and personal care: Compound W, Dermarest, Nix Americane, Boil Ease, Ting and Wartner, Boudreaux’s Butt Paste, Caldesene powder
New products: Summer’s Eve Active Collection, Summer’s Eve fragrance free line; DenTek Ultimate Dental Guard; Caldesene (updated formula)
Comments: Prestige Brands is one of the largest branded OTC companies in the US with more than 70 product families in the portfolio. Corporate sales decreased 1.3% to $963.0 million for the fiscal year ended March 31, 2019.
Revenues for fiscal 2020 were driven by continued positive consumption levels across the company’s core brands. Revenues for fiscal 2019 included the results of the divested household cleaning segment in the first quarter of fiscal 2019. Organic revenue increased 1.3% for the fiscal year driven by strong international segment growth as well as consumption gains in the company’s core brand portfolio domestically, partially offset by retailer inventory reductions.
According to CEO Ron Lombardi, “The continued focus on our three-pillar strategy and long-term brand building efforts delivered solid revenue, earnings and cash flow…as we enter Fiscal 2021, we anticipate a unique and uncertain business environment.
In the North American OTC healthcare segment, revenues totaled $219.8 million for the fourth quarter of fiscal 2020, compared to the prior year comparable quarter’s revenues of $214.9 million. The fourth quarter fiscal 2020 revenue increase was attributable to increased consumption in the Company’s core brand portfolio.
For the fiscal year 2020, reported revenues for the North American OTC healthcare segment were $859.4 million compared to $862.4 million in the prior year. Fiscal year 2020 was favorably impacted by increased consumption among the majority of core OTC brands but offset by inventory reductions at certain key retailers.
In international OTC healthcare, fiscal fourth quarter 2020 revenues totaled $31.4 million, compared to $26.1 million reported in the prior year comparable period. Revenues versus the prior year fourth quarter benefitted from strong consumption growth as well as the timing of distributor orders and shipments, partially offset by unfavorable foreign currency of approximately $1 million.
For the fiscal year 2020, reported revenues for the international OTC healthcare segment were $103.6 million versus the prior year’s revenues of $93.5 million, attributable to consumption and shipment growth in the Asia-Pacific region and particularly the company’s care brand portfolio in Australia. Growth in the fiscal year was partially offset by unfavorable foreign currency exchange rates of approximately $4 million.
As previously reported in the Happi Top 50, the company sold its household cleaning segment on July 2, 2018 and used net proceeds from the divestiture to pay down debt. For the first quarter of fiscal 2019, the household cleaning segment generated $19.8 million in revenues with no reported revenue in subsequent fiscal 2019 quarters.